Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.
The Surfers considered the implication of a Digital ILC presentation by James Paik et al. titled "Causes of death in patients with non-alcoholic fatty liver disease (NAFLD): data from national vital statistics system (NVSS)." The presentation demonstrated that liver disease, not cardiovascular, is the leading cause of death for NAFLD patients, with broad implications for treating early-stage patients. Surfers asked: If NAFLD patients "feel bad" all the time, can patient-reported outcomes become a primary measure? Shouldn't metabolic measures remain vitally important for patients most of whom are obese and exhibit concomitant Type 2 diabetes or cardiovascular disease? And which test(s) provide the greatest support for FibroScan in demonstrating positive predictive value? A tremendous amount of content and tips from Dr. Harrison and Prof. Schattenberg. You'll want to listen more than once!